Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 17,436	$ 15,128
Short-term investments	129,007	181,199
Prepaid expenses and other current assets	4,545	5,808
Total current assets	150,988	202,135
Property and equipment, net	119	165
In-process R&D	11,629	10,337
Other non-current assets	1,029	242
Total assets	163,765	212,879
Current liabilities:
Accounts payable	4,749	4,545
Accrued expenses and other current liabilities	8,879	10,179
Total current liabilities	13,628	14,724
Long-term liabilities:
Long-term debt	29,653	26,619
Other long-term liabilities	0	87
Total liabilities	43,281	41,430
Commitments and Contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.001 par value, 300,000,000 authorized as of June 30, 2025 and December 31, 2024; 172,836,922 and 172,423,223 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	173	173
Additional paid-in capital	666,817	661,276
Accumulated other comprehensive loss	(216)	(750)
Accumulated deficit	(546,290)	(489,250)
Total stockholders’ equity	120,484	171,449
Total liabilities and stockholders’ equity	$ 163,765	$ 212,879

In-process research and development.

No definition available.

Name:	svra_InProcessResearchAndDevelopment
Namespace Prefix:	svra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).